This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Leap Therapeutics, Inc. (LPTX) Reports Q2 Loss
by Zacks Equity Research
Leap Therapeutics, Inc. (LPTX) delivered earnings and revenue surprises of 7.69% and 0.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Leap Therapeutics, Inc. (LPTX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Leap Therapeutics, Inc. (LPTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Down 19.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Leap Therapeutics, Inc. (LPTX)
by Zacks Equity Research
Leap Therapeutics, Inc. (LPTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Leap Therapeutics, Inc. (LPTX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Leap Therapeutics, Inc. (LPTX) delivered earnings and revenue surprises of -9.09% and -3.85%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Leap Therapeutics, Inc. (LPTX) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Leap Therapeutics, Inc. (LPTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Leap Therapeutics, Inc. (LPTX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Leap Therapeutics, Inc. (LPTX) delivered earnings and revenue surprises of -12.50% and -6.25%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Company News for Jun 15, 2020
by Zacks Equity Research
Companies in the news are: EMAN, LPTX, VISL, CLPS
Leap Therapeutics (LPTX) Soars: Stock Adds 8.3% in Session
by Zacks Equity Research
Leap Therapeutics (LPTX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Leap Therapeutics Surges on License Agreement With BieGene
by Zacks Equity Research
Leap Therapeutics (LPTX) signs agreement with China-based BieGene granting the latter rights to develop its pipeline candidate, DKN-01. It also signs equity financing deals worth $27 million.
Zacks.com featured highlights include: Columbia Sportswear, American Woodmark, DICK'S Sporting, Alder and Leap
by Zacks Equity Research
Zacks.com featured highlights include: Columbia Sportswear, American Woodmark, DICK'S Sporting, Alder and Leap
Use Rising P/E Strategy to Grab 5 Winning Stocks
by Sanghamitra Saha
Cross the age-old barrier of low P/E investing. bet on these five stocks that boast rising P/E.
Why Leap Therapeutics (LPTX) Might Surprise This Earnings Season
by Zacks Equity Research
Leap Therapeutics (LPTX) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.